Please assess the completion status of the following clinical trial:

Trial Title: Restoration of Atrioventricular Synchrony Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meet current indications for an implantable cardioverter-defibrillator (ICD) implant with:~* QRS width \< 120 msec~* Left ventricular ejection fraction (LVEF) \< 35% (no more than 180 days prior to enrollment)~* NYHA functional class II/III~* Optimal pharmacological heart failure therapy~* PR interval \>/= 230 msec~* Ability to tolerate protocol required programming~* Access to a telephone line compatible with the LATITUDE® Communicator~* Subjects in sinus rhythm at the time of the baseline visit and who are expected to remain in sinus rhythm for the duration of the study~* Age 18 or above, or of legal age to give informed consent specific to state and national law~* Willing and capable of providing informed consent, undergoing a device implant, participating in all testing associated with this clinical investigation at an approved clinical investigational center and return to the investigational center at the intervals defined by this protocol~Exclusion Criteria:~* Previously placed pacemaker, ICD, or CRT device~* Inability or refusal to sign the Informed Consent Form~* Documented life expectancy of less than 12 months or expected to undergo heart transplant within the next 12 months~* Have tricuspid valve disease or who are likely to receive a mechanical tricuspid valve during the course of the clinical investigation~* Inability or refusal to comply with the follow-up schedule~* Have a neuromuscular, orthopedic, or other noncardiac condition that prevents subject from normal unsupported walking for the six minute hall walk test~* Have surgically uncorrected primary valvular heart disease~* Second or third degree atrioventricular block (AVB)~* Permanent or persistent atrial tachyarrhythmia that is refractory to all therapies~* Have had cardiac surgery, percutaneous coronary intervention, or myocardial infarction within 3 months of signing consent or who are likely to undergo a cardiac surgery or procedure in the foreseeable future~* Enrolled in any concurrent study unless written approval has been obtained from Boston Scientific or The Integra Group~* Women who are pregnant or plan to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Device programming modifies AV timing (Type: EXPERIMENTAL): DDD-40-BiV
- Device programming allows intrinsic AV timing. (Type: NO_INTERVENTION): VVI-40-RV

Based on this trial design, predict the completion outcome and termination type (if applicable).